Dear Editor,

Since the end of 2019, a pandemic has emerged and spread around the globe with patients presenting with acute respiratory failure. The causative agent was defined as a novel coronavirus, hence Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2), which has similar genetic properties compared with the previous outbreaks seen in the last two decades. It has affected more than a million patients and results in increased mortality, especially in elderly patients ([@b1-tard-48-3-254]).

SARS-CoV-2 disturbs the mechanism of the renin-angiotensin-aldosterone (RAAS) system. RAAS is essential in regulating blood pressure, homeostasis and the electrolyte balance. SARS-CoV-2 enters the host cell, i.e. Type II pneumocytes, via an interaction between its spike proteins and Angiontensin Converting Enzyme II (ACE II) receptors. As a consequence these receptors downregulate, leading to disinhibition of Angiotensin Converting Enzyme I on the angiotensin II. Angiotensin II (AT-II) has a myriad of effects, both regional and systemic. A relative increase in the alveolar AT-II levels leads to pulmonary vasoconstriction, increase in capillary permeability, enhanced fibrosis and eventually cytokine storm. Also, it is a robust systemic vasoconstrictor and the primary inducer of aldosterone production ([@b2-tard-48-3-254]).

In addition to hypoxemia, hypernatremia and hypokalaemia are also common in SARS-CoV-2 ARDS ([@b3-tard-48-3-254], [@b4-tard-48-3-254]). It is possible that the pathogenesis of the virus and the subsequent secondary hyperaldosteronism caused by increased AT-II levels might be responsible for the outcome ([@b5-tard-48-3-254], [@b6-tard-48-3-254]).

Spironolactone is an aldosterone antagonist which also has anti-inflammatory properties, and it is widely used in cardiac diseases ([@b7-tard-48-3-254], [@b8-tard-48-3-254]). In SARS-CoV-2 patients, diuretics like furosemide may have little value because of the profound electrolyte imbalance. On the other hand, spironolactone reverses this imbalance ([@b9-tard-48-3-254]).

In addition to proning, use of neuromuscular blocking agents and a restrictive fluid policy, we opted for administration of spironolactone and observed an improvement in terms of oxygenation. A randomised controlled trial is on the way (NCT04345887) and we believe we may have an answer to this issue in close proximity.
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